The U.S. Government Should Buy Gilead For $156 Billion To Save Money On Hepatitis C

Bike is Designed to Mimic the Symptoms of Multiple Sclerosis
January 24, 2017
Prostate Cancer Team Cracks Genetic Code to Show Why Inherited Disease Can Turn Lethal
January 25, 2017
Show all

The U.S. Government Should Buy Gilead For $156 Billion To Save Money On Hepatitis C

Access to hepatitis C treatment could increase if the government purchased a manufacturer of the primary medication.

The U.S. government could cure most Americans suffering from hepatitis C infections if it simply bought drug maker Gilead Sciences on the stock market rather than purchasing its products in the drug market.

Gilead has drawn fire for the high price of its hepatitis C drugs, Sovaldi and Harvoni, which currently cost more than $500 per pill but cure the underlying hepatitis C liver infection. But, counterintuitively, buying Gilead outright on the open market could lower hepatitis C drug costs per patient to one-third their current level. That would make it affordable to rapidly treat the 2.7 million Americans the CDC estimates still have hepatitis C.

Read full article: The U.S. Government Should Buy Gilead For $156 Billion To Save Money On Hepatitis C

Read Full Article: The U.S. Government Should Buy Gilead For $156 Billion To Save Money On Hepatitis C

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.